Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer

Mary L. Disis, Emanuel Calenoff, Graham McLaughlin, Ann E. Murphy, Wei Chen, Bernd Groner, Margit Jeschke, Nick Lydon, Elaine McGlynn, Robert B Livingston, Roger Moe, Martin A. Cheever

Research output: Contribution to journalArticle

432 Citations (Scopus)

Abstract

The HER-2/neu protooncogene is amplified and overexpressed in 20-40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER- 2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.

Original languageEnglish (US)
Pages (from-to)16-20
Number of pages5
JournalCancer Research
Volume54
Issue number1
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Immunity
Breast Neoplasms
T-Lymphocytes
Antibodies
Proteins
Antibody Formation
Carcinoma, Intraductal, Noninfiltrating
Humoral Immunity
Cell- and Tissue-Based Therapy
Helper-Inducer T-Lymphocytes
Autoimmunity
Neoplasms
Peptides
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., ... Cheever, M. A. (1994). Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Research, 54(1), 16-20.

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. / Disis, Mary L.; Calenoff, Emanuel; McLaughlin, Graham; Murphy, Ann E.; Chen, Wei; Groner, Bernd; Jeschke, Margit; Lydon, Nick; McGlynn, Elaine; Livingston, Robert B; Moe, Roger; Cheever, Martin A.

In: Cancer Research, Vol. 54, No. 1, 01.01.1994, p. 16-20.

Research output: Contribution to journalArticle

Disis, ML, Calenoff, E, McLaughlin, G, Murphy, AE, Chen, W, Groner, B, Jeschke, M, Lydon, N, McGlynn, E, Livingston, RB, Moe, R & Cheever, MA 1994, 'Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer', Cancer Research, vol. 54, no. 1, pp. 16-20.
Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Research. 1994 Jan 1;54(1):16-20.
Disis, Mary L. ; Calenoff, Emanuel ; McLaughlin, Graham ; Murphy, Ann E. ; Chen, Wei ; Groner, Bernd ; Jeschke, Margit ; Lydon, Nick ; McGlynn, Elaine ; Livingston, Robert B ; Moe, Roger ; Cheever, Martin A. / Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. In: Cancer Research. 1994 ; Vol. 54, No. 1. pp. 16-20.
@article{4f17f5eddc204ee897d70627028ce869,
title = "Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer",
abstract = "The HER-2/neu protooncogene is amplified and overexpressed in 20-40{\%} of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60{\%} of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER- 2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.",
author = "Disis, {Mary L.} and Emanuel Calenoff and Graham McLaughlin and Murphy, {Ann E.} and Wei Chen and Bernd Groner and Margit Jeschke and Nick Lydon and Elaine McGlynn and Livingston, {Robert B} and Roger Moe and Cheever, {Martin A.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
pages = "16--20",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer

AU - Disis, Mary L.

AU - Calenoff, Emanuel

AU - McLaughlin, Graham

AU - Murphy, Ann E.

AU - Chen, Wei

AU - Groner, Bernd

AU - Jeschke, Margit

AU - Lydon, Nick

AU - McGlynn, Elaine

AU - Livingston, Robert B

AU - Moe, Roger

AU - Cheever, Martin A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The HER-2/neu protooncogene is amplified and overexpressed in 20-40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER- 2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.

AB - The HER-2/neu protooncogene is amplified and overexpressed in 20-40% of invasive breast cancers. HER-2/neu protein overexpression is associated with aggressive disease and is an independent predictor of poor prognosis in several subsets of patients. The protein may also be related to cancer formation, with overexpression being detectable in 50-60% of ductal carcinomas in situ. It has been suggested that it might be possible to develop specific T-cell therapy directed against proteins involved in malignant transformation. One question is whether normal proteins that are overexpressed are appropriate targets for therapeutic immune attack. This report demonstrates that some patients with HER-2/neu-positive breast cancers have both existent CD4+ helper/inducer T-cell immunity and antibody-mediated immunity to HER-2/neu protein. Initial studies performed on 20 premenopausal breast cancer patients identified antibodies to HER-2/neu in 11 individuals. Similar antibody responses have been found in some normal individuals. The patient with the greatest antibody response was studied in detail. In addition to a humoral immune response this patient had evidence of a significant proliferative T-cell response to the HER-2/neu protein and peptides. Similar T-cell responses have been detected in additional patients. It has been assumed that patients would be immunologically tolerant to HER- 2/neu as a self-protein and that immunity might be difficult to generate. If immunity could be generated, the result might be destructive autoimmunity. The current data support the notion that HER-2/neu-specific immunity might be used in therapy without destroying normal tissue but also raises questions as to the role of existent immunity in immune surveillance and cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=0028144438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028144438&partnerID=8YFLogxK

M3 - Article

C2 - 7505195

AN - SCOPUS:0028144438

VL - 54

SP - 16

EP - 20

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -